The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Govt committed to supporting pharma companies with industry-friendly policies
It is a two dose vaccine to be administered intramuscularly at 28 days apart
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
Covaxin was earlier approved for children 12-18 years of age
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Subscribe To Our Newsletter & Stay Updated
